Meglumine Cyclic Adenylate's Treatment To Spinal Cord Injury In Rats

Cyclic adenosine monophosphate(cAMP) , one of ramification of nucleotide acid, is a kind of crucial substance with physiological activity and wide distribution in the body .As the second messenger, cAMP is regulated by adenylate cyclase (AC) and phosphodiesterase (PDE), in which AC upgrade its quantities by boosting anabolism, while PDE downhold its quantities by boosting catabolism. Recently, it is found that cAMP plays vital role in spinal cord injury (SCI), whose contents drop after SCI to cause secondary injury and regenerative obstacle .Selective phosphodiesterase 4(PDE4) inhibitor rolipram can obstruct postinjury drop of cAMP quantities to keep its concentration, as a result to reduce secondary injury and promote nerve cell regenernation after SCI. Consequently, it is feasible to supply extra cAMP to contain its concentration to obstruct secondary injury and promote nerve cell regenernation after SCI. Meglumine cyclic adenylate(MCA), a new cAMP ramification, is a kind of compound of cyclic adenylate and meglumine with same function of cAMP and better lipid-dissolving capacity,which is able to enter cell lightly and inhibit PDE4 , and so could be applied to prevent cAMP drop to treat SCI in theory . With its low-cost and less-toxicity, MCA has been used diffusely in clinics for cardivarscular disease, furthermore,it...